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Boron neutron capture therapy is a powerful anti-cancer treatment, the success of which 
depends heavily on the boron delivery agent. Enabling the real-time tracing of delivery agents 
as they move through the body is crucial to the further development of boron neutron therapy. 
In this study, we fabricate highly bio-compatible boron-10 embedded nanodiamonds using 
physical ion implantation in conjunction with a two-step annealing process. The red 
fluorescence of the nanodiamonds allows their use in fluorescence microscopy and in vivo 
imaging systems, thereby making it possible to conduct tracking in real time. The proposed 
fluorescent boron-10 embedded nanodiamonds, combining optical visibility and boron-10 
transport capability, are a promising boron delivery agent suitable for a wide range of 
biomedical applications. 
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  Radiation therapy1), chemotherapy2), and surgery3) are the three most common approaches 
to cancer treatment. Radiation therapy has undergone considerable advances in recent decades, 
particularly in the fields of photon therapy4) and particle therapy, involving protons5), neutrons6), 
and heavy particles7). Boron neutron capture therapy (BNCT) involves the use of heavy 
particles as an alternative to conventional radiation therapy for the treatment of tenacious 
cancers, such as those of the head and neck cancer8-10) and glioblastoma multiforme11, 12) 
(GBM). 
BNCT is based on the nuclear capture and fission reactions that occur when a non-
radioactive boron-10 absorbs a neutron13, 14). This form of nuclear fission produces high-
energy alpha particles and high-energy lithium-7, both of which induce ionization in the 
immediate vicinity of the reaction. The range of ionization is 4–9 µm, which is less than the 
diameter of a tumor cells. After the boron-10 ions are internalized by tumor cells, high-energy 
particles kill the tumor cells by damaging their DNA or organelles14-16). 
Many factors can affect the outcomes of BNCT treatment, particularly the delivery agents 
used for the transport of boron-10 to tumor tissue. Boron delivery agents must be low in 
toxicity17). They must permit the retention of boron-10 in the cancer tissue, while promoting 
rapid clearance from the body17). Finally, they must be traceable throughout the body18). Overall, 
an ideal delivery agent would have the ability to target cancer cells with large numbers of 
boron-10 atoms, while remaining traceable and nontoxic to the human body. High efficiency 
boron delivery agent is still under developing. One of the options is using nanoparticles to 
achieve those points. 
Nanoparticles have been used with considerable success in the diagnosis and treatment of 
cancer19). They are often combined with conventional cancer treatment drugs to enable the 
direct targeting of tumor tissue, thereby reducing the effects of toxicity on the immune system 
and normal tissue20). Nanodiamonds (NDs) provide excellent bio-compatibility21-24) and their 
surface is easily modified to facilitate the attachment of conventional drugs that kill tumor cells 
3 
 
via chemical processes25). Most previous studies in this field have focused exclusively on the 
surface of NDs (i.e., disregarding the interior of the NDs) for drug delivery or other features. 
Recently, we developed a novel technique that uses ion implantation to enable the addition of 
boron-10 to NDs for use as a boron delivery agent. Atoms implanted within NDs are stable and 
provide good bio-compatibility26). This technique allows us to add a new dimension for BNCT 
applications. 
In this work, we fabricate boron-10 embedded nanodiamonds using physical ion 
implantation in conjunction with a two-step annealing process. During the fabrication process, 
high-energy boron ions penetrate into the diamond lattice to create vacancies. Annealing is then 
used to form nitrogen-vacancy (NV) centers within the NDs (first step) and to remove graphite 
from the surface (second step). It is generally not possible to observe NDs after they enter cells 
or animal body; however, the proposed boron-10 embedded NDs with red fluorescence can be 
observed using fluorescence microscopy or an in vivo imaging system (IVIS). With optical 
visibility, boron-10 embedded NDs become an observable boron delivery agent. One has the 
chance to observe them by red fluorescence with low background signals in this wavelength 
region27). Boron-10 embedded NDs overcome the limitation that the existing boron delivery 
agents are not easy to be observed inside the cells or animal body. 
Furthermore, once combining with targeting ability by NDs surface modification28), boron-
10 embedded NDs can become akin to a kind of Trojan Horse. The Trojan people (cells) will 
pull the horses into their city (the interior of cells). In other words, boron-10 embedded NDs 
will more accumulate in tumor and create higher therapeutic efficiency. It will solve the long 
existing problem that current boron delivery agents have weak targeting performance in the 
last century. To summarize, fluorescent boron-10 embedded NDs provide a novel boron 
delivery agent to extend the practical use of NDs and open up new avenues of research for the 
further development of BNCT. 
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The NDs powder with average 100 nm in diameter from Microdiamant Co. was dissolved in 
DI water and then the solution was coated on silicon wafer. Boron-10 ions were implanted into 
NDs with energy of 30 keV, dose of 3x1015 ions/cm2 and energy 60 keV, dose of 3x1015 ions/cm2. 
After implantation, the wafer was cut to many pieces to perform different processes. The 
annealing processes were performed at 800°C for 2 hours under vacuum and 450°C for 3 hours 
under air using Nabertherm annealing furnace. X-ray photoelectron spectroscopy(XPS) spectra 
were obtained using PHI Quantera II system. Microscope fluorescence images were obtained 
by Nikon Ti-U inverted research fluorescence microscopy. The excitation wavelength range is 
560േ12.5nm and the detected emission wavelength range is 692േ40nm. In vivo imaging 
system IVIS Lumina II was used to capture IVIS fluorescence images. The excitation 
wavelength is 535 nm and the detected emission wavelength is 680 nm. 
Following boron-10 ion implantation, our first objective was to confirm that the implanted 
NDs contained boron ions. Fig. 1 presents the B 1s XPS spectra of as-implanted NDs and NDs. 
The characteristic peak of boron29) near 190 eV can be clearly observed in Fig. 1 (a). The 
measured spectra revealed that the as-implanted NDs contained boron ions and we called them 
B-NDs. For practical bio-applications, it is crucial that the nanoparticles used for tracing 
provide fluorescence of a sufficient intensity to allow observation using a microscope or other 
device. Many nitrogen atoms are included in the ND structure during fabrication. Boron-10 ion 
implantation produces many vacancies in the diamond lattice. In this study, we used high-
temperature vacuum annealing to promote the formation of NV centers to facilitate red 
fluorescence. Initial annealing under vacuum at 800°C was followed by air annealing at 450°C 
for the removal of graphite layers, which might otherwise block the fluorescence. Two-step 
annealing methods such as this have previously been used to repair the lattice of NDs and 
remove surface graphite30). We used XPS spectra to evaluate the effects of the two-step 
annealing process on B-NDs.  
All obtained XPS spectra were fitted with possible carbon chemical states31, 32). Figs. 2 (a) 
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and (b) respectively present the C 1s spectra of the original (non-implanted) NDs and as-
implanted B-NDs. The difference of calculated sp3/sp2 ratio between the original NDs and as-
implanted B-NDs is insignificant. It implies the damage caused by boron-10 ion implantation. 
Fig. 2 (c) presents the C 1s spectra of B-NDs annealed under vacuum at 800°C. The calculated 
sp3/sp2 ratio of the B-NDs increased from 2.74 before annealing to approximately 7 after 
annealing. This is a clear demonstration of how high-temperature vacuum annealing repairs the 
lattice structure of as-implanted B-NDs. Fig. 3 (d) presents the C 1s spectrum of B-NDs 
following two-step annealing. The carbide signal likely originated at the contact surface 
between the NDs and the silicon substrate. The calculated sp3/sp2 ratio of the B-NDs increases 
from 7 prior to second-stage annealing to 11.6 after this step. This clearly demonstrates the 
efficacy of air annealing at 450°C for the removal of graphite from the surface of the B-NDs. 
To summarize, first-stage annealing formed NV centers, and second-stage annealing removed 
surface graphite, thereby allowing the tracking of red fluorescence. 
In this study, we employed a microscope commonly used to observe fluorescence in biology 
labs. Fig. 3 presents fluorescence images of NDs and B-NDs obtained using the microscope 
under various conditions. Only the B-NDs that underwent the proposed two-step annealing 
process (Fig. 3 (d)) are clearly observable. Thus, it would be reasonable to expect that even 
after the B-NDs are internalized by cells, they could be observed in a similar manner. We also 
used non-invasive IVIS system to verify our findings. The IVIS system uses the full wavelength 
spectrum from high-energy blue to low-energy infrared to study disease progression, cell 
trafficking, and gene expression patterns via fluorescence or luminescence33). The detection of 
B-NDs using the IVIS system is a clear indication of the efficacy of these B-NDs in practical 
bio-applications. The emission wavelength of NV centers of maximum intensity is 
approximately 680 nm34). We used a halogen lamp light source with a wavelength of 535 nm 
to excite the samples and receive fluorescence emission signals with a wavelength of 680 nm. 
Fig. 4 presents IVIS fluorescence images of the original NDs and B-NDs under various 
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conditions. The grey image is taken by visible light camera and then the fluorescent signal is 
overlaid on this grey image. Only the colored area presented fluorescence emissions at 680 nm. 
Again, the only visible fluorescence was from B-NDs after two-step annealing. Testing was 
also conducted on NDs that underwent the proposed two-step annealing process without boron-
10 implantation. Those NDs remained invisible under the instruments used in this study. 
Visibility under a fluorescence microscope and the IVIS system provides compelling evidence 
of the practical value of the proposed B-NDs.  
In conclusion, this paper reports the fabrication of fluorescent boron-10 embedded NDs 
using boron-10 ion implantation followed by a two-step annealing process. The B-NDs 
annealed at 800°C for 2 hours under vacuum and 450°C for 3 hours under air provided red 
fluorescence of sufficient intensity to enable detection using a commercial fluorescence 
microscope as well as the IVIS system. The proposed B-NDs, combining optical visibility and 
boron-10 transport capability, are a promising boron delivery agent suitable for a wide range 
of biomedical applications. 
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Figure caption  
 
Fig. 1. B 1s XPS spectra of (a) as-implanted NDs. (b) original NDs. 
 
Fig. 2. C 1s XPS spectra of (a) Original NDs. (b) as-implanted B-NDs. (c) B-NDs annealed at 
800°C under vacuum. (d) B-NDs annealed at 800°C under vacuum and 450°C in air. 
 
Fig. 3. Microscope fluorescence images of NDs and B-NDs under different condition. (a) 
Original NDs. (b) As implanted B-NDs (c) B-NDs annealed at 800°C under vacuum. (d) B-
NDs annealed at 800°C under vacuum and 450°C in air. Scale bar: 10 μm. 
 
Fig. 4. IVIS fluorescence images of NDs and B-NDs under different condition. (a) Original 
NDs. (b) As implanted B-NDs (c) B-NDs annealed at 800°C under vacuum. (d) B-NDs 
annealed at 800°C under vacuum and 450°C in air. The grey image is taken by visible light 
camera and then the fluorescent signal is overlaid on this grey image. Only the colored area 
presented fluorescence emissions at 680 nm. 
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